Emma F Magavern

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 14

Top Topics

Clinical Decision Support

Left Atrial Appendage

Cross Sectional

Top Venues

British journal of clinical pharmacology

Arteriosclerosis, thrombosis, and vascular biology

The pharmacogenomics journal

European heart journal. Cardiovascular pharmacotherapy

This page only lists publications with an associated author ORCID identifier.

Publications

Emma F Magavern, John H McDermott, Mark J Caulfield, William G Newman
CYP2C19 genetic testing for Mavacamten and ischaemic stroke treatment: What does the result mean for cardiovascular prescribers in the UK and Europe? European heart journal. Cardiovascular pharmacotherapy (2024)
Emma F Magavern, Vikas Kapil, Manish Saxena, Ajay K Gupta, Mark J Caulfield
Use of Genomics to Develop Novel Therapeutics and Personalize Hypertension Therapy. Arteriosclerosis, thrombosis, and vascular biology (2024)
Emma F Magavern, Vikas Kapil, Manish Saxena, Ajay K Gupta, Mark J Caulfield
Use of Genomics to Develop Novel Therapeutics and Personalize Hypertension Therapy. Arteriosclerosis, thrombosis, and vascular biology 44 (4) (2024)
Emma F Magavern, Vikas Kapil, Manish Saxena, Ajay K Gupta, Mark J Caulfield
Use of Genomics to Develop Novel Therapeutics and Personalize Hypertension Therapy. Arteriosclerosis, thrombosis, and vascular biology 44 (4) (2024)
Emma F Magavern, David A van Heel, Damian Smedley, Mark J Caulfield
CYP2C19 loss of function alleles are not associated with higher prevalence of gastrointestinal bleeds in those who have been prescribed antidepressants: Analysis in a British-South Asian cohort. British journal of clinical pharmacology (2023)
Emma F Magavern, Faiza Durrani, Mehru Raza, Robin Lerner, Mohammed Riadul Islam, null null, Megan Clinch, Mark J Caulfield
British South Asian ancestry participants views of pharmacogenomics clinical implementation and research: a thematic analysis. The pharmacogenomics journal (2023)
Emma F Magavern, Andrew Hitchings, Lynne Bollington, Kurt Wilson, David Hepburn, Rachel J Westacott, Amir H Sam, Mark J Caulfield, Simon R J Maxwell
UK Prescribing Safety Assessment (PSA): The development, implementation and outcomes of a national online prescribing assessment. British journal of clinical pharmacology (2023)
Emma F Magavern, Mark J Caulfield
Equal access to pharmacogenomics testing: The ethical imperative for population-wide access in the UK NHS. British journal of clinical pharmacology (2023)
Emma F Magavern, David A van Heel, null null, Damian Smedley, Mark J Caulfield
SLCO1B1*5 is protective against non-senile cataracts in cohort prescribed statins: analysis in a British-South Asian cohort. The pharmacogenomics journal (2023)
Elizabeth Adeyeye, Carmela Maniero, Emma F Magavern, Robin E Ferner, Patricia McGettigan
Prescribing direct-acting oral anticoagulants - Mind the evidence gap. British journal of clinical pharmacology 88 (11) (2022)
Emma F Magavern, Serge Cremers
Introduction to clinical pharmacology at large. British journal of clinical pharmacology 87 (8) (2021)
Emma F Magavern, Jan Piasecki, Adam A Cohen, Jeffrey K Aronson
Ethics in clinical pharmacology: Facilitating public trust. British journal of clinical pharmacology (2021)
Emma F Magavern, Ann K Daly, Annette Gilchrist, Dyfrig A Hughes
Pharmacogenomics spotlight commentary: From the United Kingdom to global populations. British journal of clinical pharmacology (2021)
Emma F Magavern, Deepti Gurdasani, Fu L Ng, Sandra Soo-Jin Lee
Health equality, race and pharmacogenomics. British journal of clinical pharmacology (2021)